Hendrik Schulze-Koops

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 42

Top Topics

Respiratory Syndrome Coronavirus

Rheumatoid Arthritis

Top Venues

Annals of the rheumatic diseases

Nature reviews. Rheumatology

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Martin Poller, Martin M P Schulz, Hendrik Schulze-Koops, Diego Kyburz, Johannes von Kempis, Ruediger B Mueller
Does the Change of Weather Influence Disease Activity in Rheumatoid Arthritis Patients: Patients' Self-Assessment via WebApp. Journal of clinical medicine 13 (17) (2024)
Lea Grümme, Sophia Dombret, Thomas Knösel, Alla Skapenko, Hendrik Schulze-Koops
Colitis induced by IL-17A-inhibitors. Clinical journal of gastroenterology (2023)
Alla Skapenko, Hendrik Schulze-Koops
COVID-19 vaccination in individuals with inflammatory rheumatic diseases. Nature reviews. Rheumatology 19 (2) (2023)
Delila Singh, Nina Hesse, Alla Skapenko, Hendrik Schulze-Koops
A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb. RMD open 9 (1) (2023)
Alla Skapenko, Hendrik Schulze-Koops
COVID-19 vaccination in individuals with inflammatory rheumatic diseases. Nature reviews. Rheumatology 19 (2) (2023)
Fabian T H Ullrich, Alla Skapenko, Hendrik Schulze-Koops
Spontaneous abortion as differential diagnosis of intermittent glomerular proteinuria in inactive systemic lupus erythematosus. Clinical case reports 11 (7) (2023)
Delila Singh, Nina Hesse, Alla Skapenko, Hendrik Schulze-Koops
A rare side effect of methotrexate therapy: drug-induced osteopathy with multiple fractures of the lower limb. RMD open 9 (1) (2023)
Rebecca Hasseli, Jutta G Richter, Bimba Franziska Hoyer, Hanns-Martin Lorenz, Alexander Pfeil, Anne Constanze Regierer, Tim Schmeiser, Anja Strangfeld, Reinhard E Voll, Andreas Krause, Sabine Reckert, Anett Gräßler, Petra Saar, Andreas Kapelle, Marina Backhaus, Norbert Blank, Joerg Henes, Silke Osiek, Anna Knothe, Guido Hoese, Jan Brandt-Jürgens, Anja Maltzahn, Christof Specker, Ulf Müller-Ladner, Hendrik Schulze-Koops, null null, null null
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases. RMD open 9 (2) (2023)
Gerd-Rüdiger R Burmester, Bernhard Manger, Larissa Valor-Méndez, Hendrik Schulze-Koops
Joachim Robert Kalden: one of the founders of autoimmunity research and immunotherapy. Annals of the rheumatic diseases 80 (6) (2022)
Alla Skapenko, Hendrik Schulze-Koops
COVID-19 vaccination in individuals with inflammatory rheumatic diseases. Nature reviews. Rheumatology (2022)
Daniel Aletaha, Andreas Kerschbaumer, Kastriot Kastrati, Christian Dejaco, Maxime Dougados, Iain B McInnes, Naveed Sattar, Tanja Alexandra Stamm, Tsutomu Takeuchi, Michael Trauner, Désirée Mfm van der Heijde, Marieke Voshaar, Kevin L Winthrop, Angelo Ravelli, Neil Betteridge, Gerd-Rüdiger R Burmester, Johannes W J Bijlsma, Vivian Bykerk, Roberto Caporali, Ernest H S Choy, Catalin Codreanu, Bernard Combe, Mary K Crow, Maarten P T de Wit, Paul Emery, Roy M Fleischmann, Cem Gabay, Merete Lund Hetland, Kimmie L Hyrich, AnnaMaria Iagnocco, John Dudley Isaacs, Joel M Kremer, Xavier Mariette, Peter A Merkel, Eduardo F Mysler, Peter Nash, Michael T Nurmohamed, Karel Pavelka, Gyula Poor, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Anja Strangfeld, Yoshiya Tanaka, Josef S Smolen
Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the rheumatic diseases (2022)
Thomas Wimmer, Raphael Mattes, Hans-Joachim Stemmler, Fabian H Hauck, Hendrik Schulze-Koops, Stephanie-Susanne Stecher, Michael W Starck, Clemens-Martin Wendtner, Peter Bojko, Marcus Hentrich, Katharina E Nickel, Katharina S Götze, Florian Bassermann, Michael von Bergwelt-Baildon, Karsten Spiekermann
sCD25 as an independent adverse prognostic factor in adult HLH patients: results of a multicenter retrospective study. Blood advances (2022)
Andra Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L Bhatt, Carol A Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B Shapiro, Janet E Pope, Hendrik Schulze-Koops
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Annals of the rheumatic diseases 81 (11) (2022)
Josef S Smolen, Robert B M Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimmie L Hyrich, Janet E Pope, Savia de Souza, Tanja Alexandra Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd-Rüdiger R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, AnnaMaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Thea P M Vliet Vlieland, René Westhovens, Désirée Mfm van der Heijde
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals of the rheumatic diseases (2022)
Joerg Christoph Henes, Sebastian Jonas Saur, David M Kofler, Claudia Kedor, Christoph Meisner, Marion Schuett, Krusche Martin, Ina Koetter, Theodoros Xenitidis, Hendrik Schulze-Koops, Eugen Feist, null null
Tocilizumab for the Treatment of Familial Mediterranean Fever-A Randomized, Double-Blind, Placebo-Controlled Phase II Study. Journal of clinical medicine 11 (18) (2022)
Alla Skapenko, Hendrik Schulze-Koops
COVID-19 vaccination in individuals with inflammatory rheumatic diseases. Nature reviews. Rheumatology (2022)
Robert B M Landewe, Féline P B Kroon, Alessia Alunno, Aurélie Najm, Johannes W J Bijlsma, Gerd-Rüdiger R Burmester, Roberto Caporali, Bernard Combe, Richard P Conway, Jeffrey R Curtis, Ori Elkayam, Laure Gossec, Marloes W Heijstek, Lukas Haupt, AnnaMaria Iagnocco, John Dudley Isaacs, István Ábel Juhász, Suzi Makri, Xavier Mariette, Iain B McInnes, Puja Mehta, Ulf Mueller-Ladner, Hendrik Schulze-Koops, Josef S Smolen, Dieter Wiek, Kevin L Winthrop, Victoria Navarro-Compán, Pedro M Machado
EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update. Annals of the rheumatic diseases 81 (12) (2022)
Sophia Dombret, Alla Skapenko, Hendrik Schulze-Koops
Reactive arthritis after SARS-CoV-2 infection. RMD open 8 (2) (2022)
Mahta Mortezavi, David A Martin, Hendrik Schulze-Koops
After 25 years of drug development, do we know JAK? RMD open 8 (2) (2022)
Michael Czihal, Christian Lottspeich, Christoph Bernau, Teresa Henke, Ilaria Prearo, Marc Julian Mackert, Siegfried Priglinger, Claudia Dechant, Hendrik Schulze-Koops, Ulrich Hoffmann
A Diagnostic Algorithm Based on a Simple Clinical Prediction Rule for the Diagnosis of Cranial Giant Cell Arteritis. Journal of clinical medicine 10 (6) (2021)
Michael Czihal, Anton Köhler, Ilaria Prearo, Ulrich Hoffmann, Hendrik Schulze-Koops, Claudia Dechant, Siegfried G Priglinger, Marc J Mackert, Christian Lottspeich
Hyperechogenic intimal lesions and wall thickness of the temporal and facial arteries in elderly patients with arterial occlusions of the eye. RMD open 7 (3) (2021)
Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Milena A Gianfrancesco, Zara Izadi, Kimmie L Hyrich, Anja Strangfeld, Laure Gossec, Loreto Carmona, Elsa F Mateus, Saskia Lawson-Tovey, Laura Trupin, Stephanie Rush, Patricia Katz, Gabriela Schmajuk, Lindsay Jacobsohn, Leanna Wise, Emily L Gilbert, Ali Duarte Garcia, Maria O Valenzuela-Almada, Guillermo J Pons-Estel, Carolina A Isnardi, Guillermo A Berbotto, Tiffany Y-T Hsu, Kristin M D'Silva, Naomi J Patel, Lianne Kearsley-Fleet, Martin Schäfer, Sandra Lucia Euzébio Ribeiro, Samar Al Emadi, Liselotte Tidblad, And Carlo Alberto Scirè, Bernd Raffeiner, Thierry Thomas, René-Marc Flipo, Jérôme Avouac, Raphaèle Seror, Miguel Bernardes, Maria Margarida Cunha, Rebecca Hasseli, Hendrik Schulze-Koops, Ulf Müller-Ladner, Christof Specker, Viviane Angelina de Souza, Licia Maria Henrique da Mota, Ana Paula Monteiro Gomides Reis, Philippe Dieude, Elena Nikiphorou, Vanessa L Kronzer, Namrata Singh, Manuel Francisco Ugarte-Gil, Beth Wallace, Akpabio Akpabio, Ranjeny Thomas, Suleman Bhana, Wendy Costello, Rebecca Grainger, Jonathan S Hausmann, Jean W Liew, Emily Sirotich, Paul Sufka, Philip C Robinson, Pedro M Machado, Jinoos Yazdany, null null
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the rheumatic diseases 80 (9) (2021)
Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd-Rüdiger R Burmester, Francesco Carubbi, Gabriele De Marco, Roberto Giacomelli, Olivier Hermine, John Dudley Isaacs, Isabelle Kone-Paut, César Magro-Checa, Iain B McInnes, Pier Luigi Meroni, Luca Quartuccio, A V Ramanan, Manuel Ramos-Casals, Javier Rodríguez Carrio, Hendrik Schulze-Koops, Tanja Alexandra Stamm, Sander W Tas, Benjamin Terrier, Dennis G McGonagle, Xavier Mariette
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Annals of the rheumatic diseases (2021)
Rebecca Hasseli, Alexander Pfeil, Andreas Krause, Hendrik Schulze-Koops, Ulf Müller-Ladner, Christof Specker, null null
A survey to evaluate knowledge, perceptions and attitudes toward COVID-19 vaccinations among rheumatologists in Germany. Rheumatology international 41 (11) (2021)
Hendrik Schulze-Koops, Christof Specker, Alla Skapenko
Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines. RMD open 7 (1) (2021)
Rebecca Hasseli, Ulf Mueller-Ladner, Bimba F Hoyer, Andreas Krause, Hanns-Martin Lorenz, Alexander Pfeil, Jutta Richter, Martin Schaefer, Tim Schmeiser, Anja Strangfeld, Hendrik Schulze-Koops, Reinhard E Voll, Christof Specker, Anne Constanze Regierer
Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD open 7 (1) (2021)
Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd R Burmester, Francesco Carubbi, Gabriele De Marco, Roberto Giacomelli, Olivier Hermine, John Dudley Isaacs, Isabelle Kone-Paut, César Magro-Checa, Iain McInnes, Pier Luigi Meroni, Luca Quartuccio, Athimalaipet V Ramanan, Manuel Ramos-Casals, Javier Rodríguez Carrio, Hendrik Schulze-Koops, Tanja Alexandra Stamm, Sander W Tas, Benjamin Terrier, Dennis G McGonagle, Xavier Mariette
EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19. Annals of the rheumatic diseases (2021)
Muehlensiepen Felix, Sandra Kurkowski, Krusche Martin, Johanna Mucke, Robert Prill, Martin Heinze, Martin Welcker, Hendrik Schulze-Koops, Vuillerme Nicolas, Georg Schett, Johannes Knitza
Digital Health Transition in Rheumatology: A Qualitative Study. International journal of environmental research and public health 18 (5) (2021)
Anne Constanze Regierer, Rebecca Hasseli, Martin Schaefer, Bimba Franziska Hoyer, Andreas Krause, Hanns-Martin Lorenz, Alexander Pfeil, Jutta Richter, Tim Schmeiser, Hendrik Schulze-Koops, Anja Strangfeld, Reinhard E Voll, Christof Specker, Ulf Mueller-Ladner
TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD. RMD open 7 (3) (2021)
Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht, Rebecca Hasseli, Alla Skapenko
Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab. Annals of the rheumatic diseases 80 (5) (2020)
Hendrik Schulze-Koops, Klaus Krueger, Christof Specker, null null
Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al. Annals of the rheumatic diseases (2020)
Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko
Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: 'Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al' by Benucci et al. Annals of the rheumatic diseases (2020)
Robert B M Landewe, Hendrik Schulze-Koops
Response to: 'Should patients starting biologics be screened for COVID-19?' by Cardenas-de la Garza et al. Annals of the rheumatic diseases (2020)
Muehlensiepen Felix, Johanna Mucke, Krusche Martin, Sandra Kurkowski, Gerlinde Bendzuck, Ina Koetter, Vanessa Lemarié, Manuel Grahammer, Martin Heinze, Hendrik Schulze-Koops, Johannes Knitza
The virtual fishbowl: bringing back dynamic debates to medical conferences. Annals of the rheumatic diseases 80 (5) (2020)
Josef S Smolen, Philip Mease, Hasan Tahir, Hendrik Schulze-Koops, Inmaculada de la Torre, Lingnan Li, Maja Hojnik, Christophe Sapin, Masato Okada, Roberto Caporali, Jordi Gratacós, Philippe Goupille, Soyi Liu Leage, Sreekumar Pillai, Peter Nash
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Annals of the rheumatic diseases 79 (10) (2020)
Hendrik Schulze-Koops, Klaus Krueger, Christof Specker
No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al. Annals of the rheumatic diseases (2020)
Hendrik Schulze-Koops, Alla Skapenko, Andreas Krause, Klaus Krueger, Hanns-Martin Lorenz, Philipp Sewerin, Christof Specker, Ulf G Wagner, Anna Voormann, Ulf Mueller-Ladner, Reinhard E Voll
Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'. Annals of the rheumatic diseases (2020)
Claudia Kedor, Joachim Listing, Jan Zernicke, Anja Weiß, Frank Behrens, Norbert Blank, Joerg Christoph Henes, Joern Kekow, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Eva Seipelt, Christof Specker, Eugen Feist
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Annals of the rheumatic diseases 79 (8) (2020)
Robert B M Landewe, Pedro M Machado, Féline P B Kroon, Hans Wj Bijlsma, Gerd R Burmester, Loreto Carmona, Bernard Combe, Massimo Galli, Laure Gossec, Annamaria Iagnocco, John Dudley Isaacs, Xavier Mariette, Iain McInnes, Ulf Mueller-Ladner, Peter Openshaw, Josef S Smolen, Tanja Alexandra Stamm, Dieter Wiek, Hendrik Schulze-Koops
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Annals of the rheumatic diseases 79 (7) (2020)
Hendrik Schulze-Koops, Christof Specker, Klaus Krueger
Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: 'Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak' by So et al. Annals of the rheumatic diseases (2020)
Hendrik Schulze-Koops, Christof Specker, Christof Iking-Konert, Julia Holle, Frank Moosig, Klaus Krueger
Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic. Annals of the rheumatic diseases 79 (6) (2020)
Kevin L Winthrop, Gustavo Citera, David Gold, Dan Henrohn, Carol A Connell, Andrea B Shapiro, Harry Shi, Alina M Onofrei, Dimitrios A Pappas, Hendrik Schulze-Koops
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Annals of the rheumatic diseases 80 (1) (2020)